Sign In
Buy REGN
$628.73
+9.78 (+1.58%)
At Close: Jun 04, 2026
Regeneron Pharmaceuticals: Game-Changing Discoveries In Healthcare
02:45pm, Tuesday, 19'th Sep 2023
Regeneron Pharmaceuticals, Inc. is a pharmaceutical company headquartered in Tarrytown that has played a key role in the fight against COVID-19. Regeneron's revenue for the second quarter of 2023 was
Regeneron's pricing deal with federal government may have ‘far-reaching consequences,' analysts say
08:40am, Friday, 15'th Sep 2023
Regeneron Pharmaceuticals Inc.'s REGN, +0.74% agreement with the federal government to limit the list price of any new COVID monoclonal antibody commercialized as a result of their public-private part
Is Regeneron Stock Fully Valued At $820?
07:00am, Monday, 11'th Sep 2023
Regeneron stock (NASDAQ: REGN) has seen a 6% rise in a month, compared to a 1% fall for the broader S&P500 index.
Regeneron CFO Landry to retire, top accountant Fenimore to become CFO
05:03pm, Friday, 08'th Sep 2023
Regeneron Pharmaceuticals Inc. REGN, +0.66% said late Friday that Chief Financial Officer Robert E. Landry will retire in February, and Christopher Fenimore, the pharma company's current head of accou
2 Top Biotech Stocks to Buy in September
09:53am, Friday, 08'th Sep 2023
Vertex and Regeneron have delivered solid financial results and stock market performance. Both biotechs have exciting pipelines that should produce key new approvals or label expansions.
Regeneron (REGN) Gains 13% in 1 Month on FDA Nod For Eylea HD
03:02pm, Thursday, 31'st Aug 2023
Regeneron (REGN) gains 13% in a month on the FDA's approval of a higher dose of Eylea and other positive updates.
Oncology Market's Huge Potential Puts These Stocks in Focus
09:46am, Monday, 28'th Aug 2023
The oncology treatment market has been experiencing significant growth lately. Companies like Regeneron Pharmaceuticals (REGN), Merck & Co. (MRK), Novartis (NVS) and AstraZeneca (AZN) have made meanin
Is Regeneron Stock a Buy Now?
10:15am, Friday, 25'th Aug 2023
Regeneron's latest regulatory approval comes at an opportune time. The company's current lineup should continue generating growing sales.
Regeneron Announces Investor Conference Presentations
04:05pm, Wednesday, 23'rd Aug 2023
TARRYTOWN, N.Y., Aug. 23, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast management participation as follows:
Regeneron gets federal funding for next-generation COVID treatment
02:34pm, Tuesday, 22'nd Aug 2023
Regeneron Pharmaceuticals Inc. REGN, -0.32% said Tuesday that the Biomedical Advanced Research and Development Authority has agreed to support the development, manufacturing and licensure of a next-ge
Regeneron (REGN) Gets FDA Nod for Higher Dose of Eylea
12:47pm, Monday, 21'st Aug 2023
Regeneron (REGN) obtains FDA approval for a higher dose of aflibercept injection under the brand name Eylea HD for various ophthalmology indications. The regulatory body also approves Veopoz.
Cramer dubs Regeneron stock a ‘favourite' after two new FDA approvals
12:45pm, Monday, 21'st Aug 2023
Regeneron Pharmaceuticals Inc (NASDAQ: REGN) secured FDA approval for Eylea HD – a higher-dose of its treatment for Macular Degeneration on Monday. Jim Cramer is bullish on Regeneron stock Shares of
This biotech name is one of Jim Cramer's favorite stocks and he thinks it can go even higher
10:52am, Monday, 21'st Aug 2023
"I think it's going to be worth more," Jim Cramer said Monday after Regeneron got good news from the FDA on its macular degeneration treatment.
Cramer's Stop Trading: Regeneron
10:51am, Monday, 21'st Aug 2023
CNBC's Jim Cramer explains why he is keeping an eye on shares of Regeneron
Regeneron's Eylea could return to growth after nod to high-dose version- analysts
09:42am, Monday, 21'st Aug 2023
A quicker-than-expected U.S. approval for Regeneron Pharmaceuticals' high-dose eye disease drug, Eylea, should help return the blockbuster treatment back to growth in the next few years, Wall Street a
